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aimed to analyze the relationship between clinical disease activity and duration of glomerular disease.
Methods: Disease activity in adults with chronic minimal change disease, focal segmental glomerulo-
sclerosis, membranous nephropathy, and IgA nephropathy (IgAN; first diagnostic biopsy >5 years before
enrollment; Of Longstanding Disease [OLD] cohort, n ¼ 256) followed at Columbia University Medical Center
(CUMC), was comparedwith disease activity of an internal and external cohort of patientswith first diagnostic
biopsy <5 years before enrollment drawn from the Cure Glomerulonephropathy Network (CureGN cohort,
n ¼ 1182; CUMC-CureGN cohort, n ¼ 362). Disease activity was defined by (i) Kidney Disease: Improving
Global Outcomes–recommended threshold criteria for initiation of immunosuppression in primary
glomerulonephropathy (GN) and (ii) CureGN’s Disease Activity Working Group definitions for activity.
Results: No significant differences were detected among the 3 cohorts in terms of age, sex, serum
creatinine, and urinary protein-to-creatinine ratio. For each GN subtype, disease activity in the OLD cohort
was comparable with disease activity in the entire CureGN and the CUMC-CureGN cohort. When limiting
our comparisons to disease activity in incident CUMC-CureGN patients (first diagnostic biopsy within 6
months of enrollment), OLD patients demonstrated similar activity rates as incident patients.
Conclusion: Disease activity did not differ among patients with shorter versus longer duration of disease.
Such survivor patients, with long-term but persistent disease, are potentially highly informative for un-
derstanding the clinical course and pathogenesis of GN and may help identify factors mediating more
chronic subtypes of disease.
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ith advances in the management of glomerular
diseases, progression to advanced and end-stage
kidney disease due to focal segmental glomerulosclero-
sis (FSGS), membranous nephropathy (MN), and IgAN
is often measured in decades rather than months or
years. Cohort studies on patients with longstanding
glomerulonephropathies (GNs) have tried to address
the impact of acknowledged risk factors on renal sur-
vival.1,2 Most of these studies, however, have been
retrospective without collection of biospecimens,
limiting analyses on the pathophysiology of diseases.
Hence, accurate predictors of disease behavior are still
not available.
Assessment of disease activity has an important role
in clinical decision-making because many components,
such as proteinuria, hematuria, and blood pressure
control are associated with long-term outcomes.
Worsening clinical disease activity is generally
considered to reflect the activity of underlying bio-
logical disease processes and often guides management
decisions, such as initiation or discontinuation of
immunosuppression or acquisition of a repeat renal
biopsy. As we enter a realm in which biomarkers for
glomerular diseases continue to emerge, the assumption
that patients with a recent diagnosis have more active
disease, and are therefore better suited for studying the
primary biological mechanisms of GN, may be called
into question. Specifically, disease onset in GN does not
necessarily coincide with the histologic diagnosis, and
urinary abnormalities may be detectable long before
the time of kidney biopsy.
In this study, we sought to analyze the relationship
between clinical disease activity and duration of GN
using data from the Cure Glomerulonephropathy
Network (CureGN, https://curegn.org/), a prospective
multicenter cohort study on glomerular diseases funded
by the National Institutes of Health/National Institute of
Diabetes and Digestive and Kidney Diseases that began
enrollment in December 2014.3 To be eligible for the
Cure GN study, the first diagnostic kidney biopsy for
Minimal Change Disease (MCD), FSGS, MN, or IgAN had
to occur within 5 years of study enrollment. We
assessed whether patients with longstanding GN (first
diagnostic biopsy >5 years) still have disease activity,
whether this differs from patients with a more recent
diagnosis (#5 years), and how longstanding disease in-
fluences the rate of kidney function decline.
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Participants
To determine disease activity in patients with long-
standing glomerular disease, we constructed a cohort ofKidney International Reports (2020) 5, 860–871adult patients ($18 years) with chronic MCD, FSGS,
MN, and IgAN followed at CUMC, whose first diag-
nostic kidney biopsy was performed >5 years from
screening. We called this the OLD cohort. We then
compared disease activity of the OLD cohort with
disease activity of an internal and external cohort of
adult patients with more recent disease diagnoses,
drawn from the CureGN study and therefore all within
5 years of their first diagnostic biopsy for MCD, FSGS,
MN, or IgAN. The CureGN cohort is composed of pa-
tients enrolled at CUMC (20%, internal comparison
cohort) and at 69 other clinical sites (external compar-
ison cohort).
Participants in the OLD cohort met all inclusion
criteria of CureGN, with the sole exception being time
of first diagnostic biopsy. Specifically, enrollment into
the OLD cohort required the initial biopsy diagnosis to
be >5 years from the time of first clinical encounter
after December 2014. To reduce confounders, patients
were excluded from the OLD cohort if they met any of
the prespecified exclusion criteria for CureGN. Detailed
inclusion and exclusion criteria for CureGN partici-
pants have been published elsewhere.4Disease Activity
We used 2 measures of disease activity. First, we
compared rates of disease activity among cohorts us-
ing Kidney Disease: Improving Global Outcomes–
recommended treatment thresholds for initiation of
immunosuppression in primary GN. For IgAN, this
criterion was proteinuria >1000 mg/g creatinine or
>1.0 g/d despite conservative therapy. For MCD/
FSGS/MN, this criterion was proteinuria >3500 mg/g
or >3.5 g/d, or serum albumin <3.0 g/dl if proteinuria
was not available (n ¼ 2), despite conservative ther-
apy.5 Second, we compared rates of disease activity
using CureGN’s Disease Activity Working Group
definitions for activity, listed for each disease in
Table 1. For the CureGN patients, we used disease
activity at enrollment. For the OLD cohort, we
assessed disease activity at the first clinical encounter
after December 2014, simulating an enrollment visit
for these patients.Data Sources and Collection
Baseline clinical data for the OLD cohort were compiled
from the CUMC Clinical Records Online Web Network
(CROWN) and self-reported demographic information.
CureGN participants’ data, collected from each site on a
Web-based data source (CureGNLink), were made
available for analysis by the CureGN Data Coordinating
Center.861
Table 1. CureGN’s definitions of disease activity
Diagnosis Disease activity criteria
IgAN and HSPN  Hematuria on urinalysis: $1þ (small blood, 11–25 RBC/HPF)
 24-h urine protein >500 mg
 UPCR >0.3 g/g
FSGS  24-h urine protein >1 g (adults)
 24-h urine protein >1 g normalized to 1.73 m2 BSA
(children <1.73 m2)
 UPCR >1 g/g
MN  24-h urine protein >1 g (adults)
 24-h urine protein >1 g normalized to 1.73 m2 BSA
(children <1.73 m2)
 UPCR >1 g/g
MCD  UPCR >1 g/g or 24-h urine >1 g
 Documented by clinical records or nephrologist of the following:
pattern within the past 12 months of frequently relapsing (2 re-
lapses in 6 mo or 4 relapses in 12 mo) or corticosteroid-
dependent (relapse on alternate-day corticosteroids or within 14
d of ceasing therapy with corticosteroids) nephrotic syndrome
 $1 relapse in the 12 mo before enrollment
 Immunosuppressive medication at enrollment to include current
use of corticosteroids, CNI (cyclosporine or tacrolimus), myco-
phenolate, azathioprine, or Acthar. Additional criteria include
alkylating agent (cyclophosphamide or chlorambucil) within 3 mo
or rituximab or other anti-CD20 monoclonal antibody within 6 mo
before enrollment
BSA, body surface area; CNI, calcineurin inhibitor; FSGS, focal and segmental glo-
merulosclerosis; HSPN, Henoch-Schönlein purpura nephritis; IgAN, IgA nephropathy;
MCD, minimal change disease; MN, membranous nephropathy; RBC/HPF, red blood
cells per high power field; UPCR, urinary protein-to-creatinine ratio.
To define the disease as active, $1 criterion for each disease should be satisfied.
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Statistical analysis was performed using SPSS17.0
software (IBM Corp., Armonk, NY). Qualitative vari-
ables were expressed as number and percentage,
compared using the nonparametric Kruskal-Wallis test
and the Mann-Whitney test. Continuous variables were
expressed as median value (interquartile range–SD)
when normally distributed; data were compared using
1-way analysis of variance with Bonferroni post hoc
test. A significance level of <0.05 was accepted.
Ethical Considerations
OLD patients were enrolled into an ongoing study on
the genetics of chronic kidney disease, a National In-
stitutes of Health–funded study in which patients
provide written informed consent for de-identified
data-sharing. All CureGN participants were informed
of the protocol and gave their written consent before
participating in the CureGN study. The project and




From December 2014 through May 2018, 256 adult
patients were screened at CUMC and included in the
OLD cohort. During this period, 2013 patients were
enrolled into the CureGN study. Fifty-three were
excluded from this analysis because their first862diagnostic kidney biopsy, on review, was done >5
years before the enrollment visit. Of the remaining
1960 CureGN patients, 1182 were adults (>18 years) at
enrollment, of whom 362 (31%) had been enrolled at
CUMC. Our analyses were therefore conducted
comparing the abovementioned OLD cohort patients
(n ¼ 256) with longstanding glomerular disease, with
both the CUMC-CureGN cohort (n¼ 362) and the whole
CureGN adult cohort (n ¼ 1182).
Baseline Characteristics Divided by Disease
Group
Demographic data for patients included in the final
analysis are summarized in Table 2, with each cohort
divided by disease group (MCD, FSGS, MN, and IgAN).
Age at screening did not differ among the 3 cohorts. As
expected, the OLD cohort had a significantly longer
course of disease compared with the CureGN and
CUMC-CureGN cohorts. Therefore, patients in the OLD
cohort were diagnosed at a younger age when
compared with their CureGN counterparts.
Clinical and laboratory data are summarized in
Table 3. No significant differences were detected in
serum creatinine and proteinuria among the 3 cohorts
and across the 4 disease groups. Microscopic hematuria
on urinalysis was significantly lower for patients with
IgAN in the OLD cohort than in CureGN patients (P <
0.001).
Overall, 75% of patients in the OLD cohort had
completed at least 1 course of immunosuppression
before their screening evaluation; 33% had tried at
least 3 different rounds of immunosuppression. How-
ever, at the time of their screening evaluation, OLD
patients were less likely than CureGN or CUMC-
CureGN cohort patients to be on any immunosup-
pression. These rates varied by disease type: for MCD,
33% of OLD patients were on no immunosuppression
(vs. 25% in CureGN and 20% in CUMC-CureGN); for
FSGS, 67% of OLD patients were on no immunosup-
pression (vs. 53% in CureGN and 52% in CUMC-
CureGN); for MN, 75% of OLD patients were on no
immunosuppression (vs. 58% in CureGN and 66% in
CUMC-CureGN); and for IgAN, 89% of OLD patients
were on no immunosuppression (vs. 68% in CureGN
and 64% in CUMC-CureGN).
Disease Activity
Using Kidney Disease: Improving Global Outcomes–
recommended treatment thresholds for initiation of
immunosuppression as our primary marker of disease
activity, we compared rates of disease activity among
the 3 cohorts (OLD, CureGN, and CUMC-CureGN) for
each disease group (MCD, FSGS, MN, and IgAN)
(Figure 1). The OLD cohort met these prespecifiedKidney International Reports (2020) 5, 860–871
Table 2. Demographics at enrollment by diagnosis
Demographics































Male 68 (43) 25 (54) 14 (42) 145 (48) 56 (59) 54 (66)a 213 (64) 70 (64) 37 (61) 229 (58) 68 (61) 49 (61) 655 (55) 219 (60) 154 (60)































































White 109 (69) 36 (78) 25 (76) 169 (56) 56 (59) 58 (71) 234 (70) 72 (66) 50 (82) 286 (73) 76 (68) 53 (66) 798 (68) 240 (66) 186 (73)
Black 24 (15) 3 (7) 3 (9) 86(29) 15 (16)a 15 (18) 54 (16) 15 (14) 5 (8) 18 (5) 3 (3) 2 (3) 182 (15) 36 (10)a 25 (10)a
Asian 17 (11) 3 (7) 2 (6) 18 (6) 7 (7) 3 (4) 28 (8) 15 (14) 4 (7) 53 (14) 19 (17) 20 (25)a 116 (10) 44 (12) 29 (11)









0 0 0 4 (1) 0 0 0 0 0 2 (1) 0 1 (1) 6 (1) 0 1 (0)
Unknown 4 (3) 2 (4) 0 19 (6) 15 (16) 0 13 (4) 7 (6) 0 25 (6) 12 (11) 0 61 (5) 36 (10) 0
Missing 0 0 3 (9) 0 0 5 (6) 0 0 2 (3) 0 0 2 (3) 0 0 12 (5)
Ethnicity
Not Hispanic 146 (92) 42 (91) 26 (79) 245 (82) 65 (68) 64 (78) 295 (89) 98 (90) 50 (82) 321 (82) 88 (79) 68 (85) 1007 (85) 293 (81) 208 (81)
Hispanic 12 (8) 4 (9) 5 (15)a 49 (16) 29 (31)a 15 (18) 29 (9) 11 (10) 9 (15) 68 (17) 24 (21) 10 (13) 158 (13) 68 (19) 39 (15)
Unknown 0 0 0 6 (2) 1 (1) 1 (1) 8 (2) 0 0 2( (1) 0 1 (1) 16 (1) 1 (0) 2 (1)
Missing 0 0 2 (6) 0 0 2 (2) 0 0 2 (3) 1 0 1 (1) 1 (0) 0 7 (3)
Family history of
kidney disease
No 112 (71) 34 (74) 29 (88) 181 (60) 46 (48) 68 (83)a,b 224 (67) 73 (67) 57 (93)a,b 263 (67) 68 (61) 59 (74) 780 (66) 221 (61) 213 (83)a,b
Yes 42 (27) 12 (26) 4 (12) 113 (38) 47 (49) 17 (14) 94 (28) 33 (30) 3 (5) 116 (30) 43 (38) 20 (25) 365 (31) 135 (37) 41 (16)
Unknown 4 (3) 0 0 6 (2) 2 (2) 0 14 (4) 3 (3) 1 (2) 13 (3) 1 (1) 1 (1) 37 (3) 6 (2) 2 (1)
CUMC, Columbia University Medical Center; CureGN, Cure Glomerulonephropathy Network; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; MCD,
minimal change disease; MN, membranous nephropathy; OLD, of longstanding disease.
aP < 0.05 for comparison against CureGN cohort.
bP < 0.05 for comparison against CUMC-CureGN cohort.





























































































Table 3. Clinical and laboratory data at enrollment by diagnosis
Clinical and
Laboratory Data












































121/74 121/75 122/76 125/77 122/78 127/80 127/77 130/78 130/80 122/78 121/80 127/80 125/78 125/80 127/80
HTN in history 50 (32) 20 (43) 14 (42) 175 (58) 57 (60) 54 (66) 199 (60) 60 (55) 51 (84)a,b 217 (55) 67 (60) 59 (74)a,b 641 (54) 204 (56) 178 (70)a,b



































$90 72 (51) 16 (35) 19 (58) 56 (21) 12 (13) 17 (21) 89 (30) 28 (26) 7 (11) 94 (26) 20 (18) 10 (13) 311 (29%) 76 (21) 53 (21)
60#n<90 43 (30) 15 (33) 12 (36) 57 (21) 20 (21) 22 (27) 96 (32) 25 (23) 20 (33) 81 (23) 18 (16) 22 (28) 277 (26%) 78 (22) 76 (30)
30#n<60 23 (16) 10 (22) 1 (3) 87 (33) 22 (23) 24 (29) 85 (28) 22 (20) 22 (36) 124 (35) 41 (37) 26 (33) 319 (30%) 95 (26) 73 (29)
15#n<30 1 (1) 0 0 46 (17) 18 (19) 13 (16) 29 (10) 13 (12) 8 (13) 49 (14) 16 (14) 19 (24) 125 (12%) 47(13) 40 (16)
<15 2 (1) 1 (2) 1 (3) 20 (8) 10 (11) 6 (7) 1 (0) 0 4 (7) 8 (2) 2 (2) 3 (4) 31 (3%) 13 (4) 14 (5)































n ¼ 300 n ¼ 87 n ¼ 80
Urinalysis:
blood >1þ
165 (42) 48 (43) 23 (29)a,b
BMI, body mass index; BP, blood pressure; CUMC, Columbia University Medical Center; CureGN, Cure Glomerulonephropathy Network; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; HTN, hypertension; IgAN,
IgA nephropathy; MCD, minimal change disease; MN, membranous nephropathy; UPCR, urinary protein-to-creatinine ratio.
aP < 0.05 for comparison against CureGN cohort.
bP < 0.05 for comparison against CUMC-CureGN cohort.





























































































Figure 1. Treatment thresholds across disease groups. Treatment threshold cutoff for IgA nephropathy (IgAN) was urinary protein-to-creatinine
ratio (UPCR) >1 g/g or 24-hour urine protein >1 g, despite optimal conservative therapy. Treatment threshold cutoff for minimal change
disease (MCD), focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN) was UPCR >3.5 g/g or 24-hour urine protein
>3.5 g/d (or serum albumin <3.0 g/dl if proteinuria was not available), despite conservative therapy. CUMC, Columbia University Medical Center;
CureGN, Cure Glomerulonephropathy Network; KDIGO, Kidney Disease: Improving Global Outcomes; OLD, of longstanding disease.
E Delbarba et al.: Persistent Disease Activity in Glomerular Diseases CLINICAL RESEARCHthreshold criteria at rates equal to those seen in CureGN
participants at enrollment. Next, we used the CureGN’s
Disease Activity Working Group definitions to
compare disease activity (Table 1). Using these more
conservative cutoffs, all 3 cohorts showed higher rates
of disease activity, but we detected no difference in
activity between OLD patients versus CureGN patients
via this metric (Figure 2). Disease activity by cohort
across diagnoses using the CureGN’s Disease Activity
Working Group definitions is summarized in Table 4.
When we subdivided the CUMC-CureGN cohort into
incident and prevalent patients (defined as diagnostic
biopsy within 6 months of enrollment vs. diagnostic
biopsy 6 months to 5 years before enrollment, respec-
tively), the OLD cohort demonstrated similar activity
rates as incident or prevalent CUMC-CureGN patients
with MCD, FSGS, and IgAN groups. Conversely, pa-
tients with MN in the prevalent CUMC-CureGN group
showed lower disease activity when compared with the
OLD cohort (P ¼ 0.005).
Repeat Biopsies
In the OLD cohort, 86 of 256 patients (34%) underwent
a second native kidney biopsy, compared with 25 of
1182 (2%) patients in the CureGN cohort (Figure 3;Kidney International Reports (2020) 5, 860–871Supplementary Table S1). Patients who underwent a
second biopsy were divided relatively equally among
the 4 disease groups. In most cases, the repeat biopsy
did not change diagnosis. In cases in which the diag-
nosis had changed (OLD: n ¼ 9; CureGN: n ¼ 3), the
most common findings were segmentally sclerotic
glomeruli in a patient previously diagnosed with MCD.
Analyzing choices made by clinicians after additional
biopsies in the OLD cohort, in 49% of the cases (50 of
103 biopsies) a change regarding immunosuppression
was made, whether starting or changing immunosup-
pression (46%) or stopping therapy (3%). In patients
with IgAN undergoing repeat biopsy for worsening
proteinuria (presumed ongoing activity), only 6% had
T2 lesions suggestive of advanced chronicity, 88% had
mesangial proliferation (M1), and 38% had endocapil-
lary proliferation (E1). In patients with IgAN under-
going repeat biopsy for declining eGFR without change
in proteinuria (presumed chronicity), 50% had T2 le-
sions and 0% had E1 lesions.
DISCUSSION
Although the onset of glomerular diseases can be acute
and severe, these diseases often become slowly pro-
gressive forms of chronic kidney disease. Because the865
Table 4. Disease activity by cohort across diagnoses
n % MCD FSGS MN IgAN
OLD 33 (91) 82 (57) 61 (69) 80 (74)
CureGN 158 (87) 300 (57) 332 (62) 392 (74)
CUMC-CureGN 46 (87) 95 (59) 109 (55) 112 (78)
Incidenta 11 (91) 42 (64) 39 (74) 56 (80)
Prevalentb 35 (86) 53 (55) 70 (44) 56 (75)
CUMC, Columbia University Medical Center; CureGN, Cure Glomerulonephropathy
Network; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; MCD,
minimal change disease; MN, membranous nephropathy; OLD, of longstanding disease.
aIncident, diagnostic biopsy within 6 mo of enrollment vs. diagnostic biopsy 6 mo to 5 yr
before enrollment.
bPrevalent, diagnostic biopsy 6 mo to 5 yr before enrollment.
cThe OLD cohort was significantly more active than the CUMC-CureGN Prevalent cohort
(P ¼ 0.005), and the CUMC-CureGN Incident than the CUMC-CureGN Prevalent cohort
(P ¼ 0.003).
Data are given as number of patients in each cohort (n), and percentage of patients
with active disease (%).
Disease activity between the OLD/CureGN/CUMC-CureGN cohorts, in the 4 disease
subtypes, was compared using Kruskal-Wallis test: MCD, P ¼ 0.837; FSGS, P ¼ 0.960;
MN, P ¼ 0.194; IgAN, P ¼ 0.690.
Disease activity between the OLD/CUMC-CureGN Incident/CUMC-CureGN Prevalent
cohorts, in the 4 disease subtypes, was compared using Kruskal-Wallis test: MCD, P ¼
0.773; FSGS, P ¼ 0.630; MN, P ¼ 0.002c; IgAN, P ¼ 0.660.
CLINICAL RESEARCH E Delbarba et al.: Persistent Disease Activity in Glomerular Diseasespattern of these diseases evolves over time, longer
follow-up is required to assess patient outcomes. In this
study, we examined disease activity in the 4 leading
primary glomerular diseases (MCD, FSGS, MN, and
IgAN), comparing activity between adult patients with
longstanding disease (OLD cohort) and adult patients
with recent onset of disease enrolled in the CureGN
study. The median time since first diagnostic kidney
biopsy for OLD patients was 10 years, compared with 1Figure 2. Disease activity at enrollment/screening according to Cure Glom
Columbia University Medical Center; FSGS, focal segmental glomeruloscl
membranous nephropathy; OLD, of longstanding disease.
866year for CureGN-enrolled patients. Using Kidney Dis-
ease: Improving Global Outcomes–recommended
treatment thresholds as a marker of persistent disease
activity, we found no difference in activity status be-
tween patients in the OLD cohort and CureGN partic-
ipants. We next categorized patients by CureGN’s
Disease Activity Working Group criteria, which were
created by a group of GN experts to be as unambiguous
and practically useful as possible in a large cohort,
advocating sensitivity rather than specificity. Using
these CureGN-based activity definitions, the OLD
cohort again displayed equal disease activity rates as
CureGN participants. Interestingly, the OLD cohort
showed activity rates more comparable with incident
patients rather than prevalent patients. Our findings
highlight that, in some patients, glomerular diseases
remain persistently active far into their disease course.
Incidence rates of primary glomerular diseases have
been well-documented, and long-term clinical out-
comes for these conditions have been reported.6–10
Nevertheless, the literature is comparably bare in
reporting persistence of disease activity many years
after clinical onset. Our study presents a unique
approach to this population by analyzing patients in
terms of disease activity rather than their chronic
kidney disease or end-stage kidney disease status.
Studies on disease activity generally focus on second-
ary forms of GN,11,12 or recurrence of primary GN aftererulonephropathy Network (CureGN) disease activity criteria. CUMC,
erosis; IgAN, IgA nephropathy; MCD, minimal change disease; MN,
Kidney International Reports (2020) 5, 860–871
Figure 3. Proportions of patients who underwent an additional kidney biopsy across disease groups. CUMC, Columbia University Medical
Center; CureGN, Cure Glomerulonephropathy Network; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; MCD, minimal
change disease; MN, membranous nephropathy; OLD, of longstanding disease.
E Delbarba et al.: Persistent Disease Activity in Glomerular Diseases CLINICAL RESEARCHkidney transplantation.13,14 Patients with long-
standing, primary glomerular disease are generally
considered less active than patients with recent onset of
the disease.
Our study stands alongside the few prior studies
that have carefully examined longstanding forms of
glomerular diseases in challenging this assumption. A
study of 340 Chinese adults with MCD reported that
nearly half continued to have flares more than 10 years
past their initial presentation.15 In our OLD cohort, the
proportion of persistent MCD relapsers was even
higher. Kanigicherla et al.16 analyzed long-term out-
comes of persistent disease and relapse rates in 128
patients with MN followed over a median of 12 years:
28% did not achieve remission (complete or partial),
and 31% of the patients who reached partial remission
experienced at least 1 relapse. In our OLD cohort, 51%
of patients with MN met treatment threshold at time of
screening, which is a fixed time-point, suggesting that
the proportion would have been even higher during
the median 10 years since biopsy. Other than protein-
uria, the magnitude and persistence of hematuria dur-
ing follow-up have been demonstrated to have a
significant influence on the progression of disease in
patients with IgAN.17 When time-averaged, a recent
study reported that, in 46% of patients with IgAN
followed for a mean period of 14 years, hematuria
disappeared. This proportion seems low when
compared with that of our OLD cohort without hema-
turia (71%), but our data were collected at screening
and not repeated over time. Notably, with regard to
proteinuria, only 7% of the OLD patients with IgAN
met criteria for complete remission.
Patients in the OLD cohort had a significantly longer
disease course and were diagnosed at a younger ageKidney International Reports (2020) 5, 860–871than their CureGN counterparts. Despite having
chronic, but persistently active, disease, renal function
in the OLD cohort at screening was comparable with
that of CUMC-CureGN patients. Moreover, renal func-
tion over an 8-year time window was similar in the 2
cohorts, though OLD patients had been diagnosed, on
average, 9 years earlier in their course than the CUMC-
CureGN patients (Figure 4). Proteinuria has always
been recognized as one of the most important risk
factors for the decline of renal function over time in
primary GN18–21; the effects become evident in long-
term follow-up. The gap between the serum creati-
nine slopes of the 2 cohorts should increase over time,
and thus the lack of such an increase suggests a sur-
vivor benefit in OLD patients. If younger age at diag-
nosis is implicated in slower decline of renal function,
this must be assessed in further studies along with
other potential protective factors.
The significantly higher rate of repeat biopsies
in OLD patients (34%) further emphasizes marked
disease activity in this population and associated clin-
ical challenges for nephrologists. Many studies have
reassessed disease activity by biopsy in lupus
nephritis,22–26 but this same sort of attention to repeat
biopsies in primary GN has not been routine. In this
study, the most frequent reasons why patients with
MCD or FSGS were rebiopsied were therapy-resistance
or corticosteroid-dependent/frequently relapsing dis-
eases. As reaffirmed by a recent study on the clinical
course of MCD with onset in adulthood,6 a missed
diagnosis of FSGS is often suggested to explain corti-
costeroid resistance, which occurred for 6 patients
in the OLD cohort and 7 in the CureGN study.
Conversely, assessing whether worsening proteinuria
and/or renal function were driven by active disease or867
Figure 4. Serum creatinine over time in of longstanding disease (OLD) and Columbia University Medical Center (CUMC)–Cure Glomerulone-
phropathy Network (CureGN) cohorts. aPoint 0 marks enrollment/screening.
CLINICAL RESEARCH E Delbarba et al.: Persistent Disease Activity in Glomerular Diseasesthe result of a chronic process was the primary reason
for second biopsies of patients with MN and IgAN.
These data show the importance of histology to help
decision-making in management of patients with
longstanding glomerular diseases. Although the sample
size of repeat biopsies in these cohorts is small, in the
subgroup with IgAN, we gleaned some information on
how well disease activity assessments correlate with
histology using Oxford Classification scores: T2 lesions
were more common in patients with presumed chro-
nicity, whereas M1 and E1 lesions were the hallmark in
patients with presumed ongoing activity. Our study
has notable limitations. Principally, the OLD cohort is
almost certainly affected by some degree of selection
bias, as it includes patients who still require follow-up
at a tertiary care center >5 years after diagnosis and
presumably have better access to health care. Hence,
these patients may be more active in their disease states
than patients of similar disease vintage followed in
nonacademic medical settings. The high repeat biopsy
rate of the OLD cohort may reflect the preceding con-
siderations. Our criteria for activity rely principally on
creatinine, proteinuria, and hematuria, and do not take
into account other acknowledged markers of activity
and disease progression, such as phospholipase A2
(PLA2R) antibodies for MN, and blood pressure and
histologic findings for all the 4 GNs. Data collection in
this study was not uniform. The OLD cohort data were
analyzed retrospectively; data collection on CureGN
patients combined retrospective collection from
chart review and prospective collection starting at
enrollment. Reporter bias likely affected some data
points, notably family history and medication expo-
sures. However, the laboratory-based data points used
for analysis of disease activity in this study are objec-
tive and fairly easy to confirm, limiting the effect of
such bias.
In conclusion, this study identified a subset of pa-
tients with longstanding MCD, FSGS, MN, and IgAN,
who had neither sustained remission nor progression to868end-stage kidney disease and therefore necessitated
regular nephrology care at a tertiary care center >5
years after diagnosis. These patients are notable in
having clinical phenotypes similar to those of patients
with newly diagnosed glomerular disease. This subset
of patients likely exists within the CureGN cohort, but
in the absence of reliable biomarkers, it will take a
decade or more of follow-up to identify the OLD subset
within the CureGN patients. Such survivor patients,
with long-term but persistently active disease, may
represent a special subpopulation lacking progression
factors or enriched in protective factors. They are
difficult to identify at time of biopsy and present a
challenge to clinicians, who must balance the need to
treat ostensibly active disease with side effects of sec-
ond- or third-line therapies. At the moment, there are
no validated biomarkers that have been shown to
reflect the underlying pathological mechanisms oper-
ating in the individual GNs, and this is supported by
the high rate of repeat biopsies performed in the OLD
cohort. OLD patients are therefore potentially highly
informative for understanding the clinical course and
pathogenesis of glomerulopathies and identifying
subtypes of disease. The characteristics of the OLD
cohort suggest that factors mediating disease activity
may be distinct from factors mediating progression.
Unlocking this pathophysiology, in turn, can identify
potential treatment targets for more chronic variants of
disease and present a framework for personalized di-
agnostics and therapeutics.
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